Coastal Infusion Administers Krystexxa®
| J-Code | J2507 |
|---|---|
| Manufacturer | Amgen |
| First Approved | 09/15/2010 |
Coastal Infusion can administer your Krystexxa prescription at any of our south Florida locations.
Krystexxa (pegloticase) is used to treat adult patients with severe chronic tophaceous gout, a condition where uric acid develops in the blood, then crystallize in joints and tissues, forming tophi (stones) that cause pain and joint damage. Krystexxa is only used in patients who cannot control their uric acid levels even at maximum doses of conventional xanthine oxidase inhibitors.
The active substance in Krystexxa, pegloticase, contains an enzyme called uricase. Uricase breaks down uric acid into another substance, allantoin. This lowers the levels of uric acid in the blood and allows crystals in the joints to dissolve, slowly shrinking the tophi.
What It Treats
Krystexxa is used to treat chronic Gout.
Prescribed By
Krystexxa is most often prescribed by Rheumatologists, Nephrologists, and Podiatrists.
How it’s Administered
Krystexxa is administered by intravenous infusion. Krystexxa infusions take about two hours.
Frequency
Krystexxa is generally administered every two weeks for 6 to 12 months.
Additional Resources
The information on this page is compiled from a variety of online sources. Coastal Infusion has made every effort to verify its accuracy, but patients are advised to discuss any planned or current treatments with their doctor. Report inaccuracies